In Reply to 'sokol'
AXON - strange I think. The stock is trading up pre-market at about $19.46, but the morning news for the AXON is: BASEL, Switzerland, April 11, 2017 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON) ("Axovant"), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the pricing of its underwritten public offering of 6,742,179 of its common shares at a price to the public of $18.54 per share. Gross proceeds to Axovant from the offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 1,011,326 of its common shares on the same terms and conditions. The offering is expected to close on April 17, 2017, subject to customary closing conditions.
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM